

ECULIZUMAB (AND BIOSIMILAR) ORDER FORM

- Soliris (eculizumab) Bkembv (eculizumab-aeab)
 Dispense As Written (DAW)

Will substitute for biosimilar or reference product based on insurance and availability

PATIENT INFORMATION

Patient Name: _____ DOB: _____
 Mobile Number: _____ Patient Weight: _____ kg
 Allergies: _____
 Patient has known difficult venous access. Comments: _____
 New Start Therapy | Continuation of Therapy & Date of last dose (if applicable): _____

DIAGNOSIS (Provider must specify)

- Myasthenia Gravis (without acute exacerbation), ICD 10: G70.00
 Myasthenia Gravis with acute exacerbation, ICD 10: G70.01
 Neuromyelitis Optica Spectrum Disorder, ICD 10: G36.0
 Other: _____

PROVIDER INFORMATION

Provider Name (print name): _____ Provider NPI: _____
 Signature: _____ Date: _____
 Contact Name: _____ Phone: _____ Fax: _____
 Email Address: _____

Prerequisites to treatment – ensure the following information is complete and attached with referral:

- Demographics Labs and tests supporting diagnosis Office/progress notes

PRE-MEDICATION (Not typically indicated)

- Acetaminophen (Tylenol) 500 mg PO Famotidine 20 mg IV Methylprednisolone (Solu-Medrol) 125 mg IVP
 Benadryl 25mg PO Cetirizine (Zyrtec) 10 mg PO
 Other: _____ Dose: _____ Route: _____

MEDICATION

MEDICATION	DOSE / FREQUENCY	ROUTE
Soliris	<input type="checkbox"/> Initial: 900 mg weekly X 4 weeks, 1200 mg week 5, then 1200 mg every 2 weeks thereafter. <input type="checkbox"/> Maintenance: 1200 mg every 2 weeks <input type="checkbox"/> Other: _____ _____ _____	IV

LABS / SPECIAL INSTRUCTIONS

Order valid for 1 year from date of signature unless otherwise specified here: _____

FAX NUMBERS:

- CT: 203.433.0621 MA: 413.296.8482 NC: 919.984.8698 NY: 631.250.6020 SC: 864.973.6279
 FL: 904.877.9270 MD: 240.224.8607 NH: 603.217.5371 OH: 937.871.4594 VA: 703.202.0499
 ME: 207.407.7272 NJ: 201.581.4521 PA: 610.273.5998